S-1/A: BioCardia Amends Underwriting Agreement, Delays S-1 Effective Date

BioCardia, Inc. filed an amendment to its S-1 registration statement, primarily updating its engagement agreement with H.C. Wainwright & Co., LLC for capital raising services and delaying the effective date.

Summary

• This filing is Amendment No. 1 to BioCardia, Inc.'s Form S-1 registration statement (File No. 333-290283), presented as an exhibits-only filing with the remainder of the registration statement unchanged and omitted.
• The primary update includes an amended engagement letter with H.C. Wainwright & Co., LLC, designating them as the exclusive underwriter or placement agent for future securities offerings.
• H.C. Wainwright & Co., LLC is entitled to a cash fee of 7.0% of aggregate gross proceeds from offerings, reduced to 3.5% for 'Excluded Investors'.
• A management fee of 1.0% of gross proceeds will also be paid to H.C. Wainwright & Co., LLC.
• Expense allowances for H.C. Wainwright & Co., LLC include $25,000 for non-accountable expenses (up to $50,000 for public offerings) and up to $50,000 for legal and other out-of-pocket expenses (up to $90,000 for public offerings).
• A 'tail' provision grants H.C. Wainwright & Co., LLC compensation for 12 months post-termination for capital raised from investors they engaged during the term.
• H.C. Wainwright & Co., LLC holds a right of first refusal for future capital-raising financings for 6 months following each offering.
• The engagement term with H.C. Wainwright & Co., LLC, initially 60 days from February 26, 2024, has been repeatedly extended through amendments on March 13, 2025, May 9, 2025, July 28, 2025, and September 3, 2025.
• The registration statement's effective date is delayed until a further amendment is filed or the SEC determines it.

Sentiment

Score: 3

Explanation: The repeated extensions of the engagement agreement and the explicit delay in the registration statement's effective date indicate challenges in securing financing and proceeding with a public offering, suggesting a negative short-term outlook despite the active pursuit of capital.

Positives

• Secured an exclusive engagement with H.C. Wainwright & Co., LLC for capital raising, indicating an active pursuit of necessary financing.
• The engagement agreement includes a 'tail' provision and right of first refusal, which could provide continuity in capital raising efforts and a dedicated partner for future financings.

Negatives

• The repeated extensions of the engagement term with H.C. Wainwright & Co., LLC suggest challenges in completing a capital raise or achieving an effective registration statement within initial timelines.
• The explicit delay in the effective date of the registration statement indicates that the proposed public sale is not imminent, potentially prolonging the company's access to public capital.
• The compensation structure for H.C. Wainwright & Co., LLC (7.0% cash fee, 1.0% management fee, and significant expense allowances) is substantial and could lead to considerable dilution for existing shareholders upon a successful offering.

Risks

• The consummation of any offering is subject to market conditions and H.C. Wainwright & Co., LLC's internal approvals, with no guarantee of success.
• H.C. Wainwright & Co., LLC's involvement is on a 'reasonable best efforts basis,' meaning there is no firm commitment to purchase securities, introducing uncertainty regarding capital availability.
• The company is obligated to pay H.C. Wainwright & Co., LLC up to $15,000 (or $50,000 for public offerings) in out-of-pocket expenses even if an offering is not carried out, incurring costs without securing capital.
• The company faces potential liability for claims related to actions or omissions, with indemnification provisions for H.C. Wainwright & Co., LLC, which could expose the company to legal and financial risks.
• The company's ability to raise capital is critical for its operations, and delays or failure to secure financing could significantly impact its strategic initiatives and financial health.

Future Outlook

The company intends to proceed with a proposed sale to the public as soon as practicable after the registration statement becomes effective, which is currently delayed pending further amendment or SEC determination. The ongoing engagement with H.C. Wainwright & Co., LLC indicates a continued focus on raising capital through various offering types.

Industry Context

The biotechnology and medical device sectors often require significant capital investment for research, development, and commercialization. Companies in these industries frequently engage investment banks for equity offerings to fund operations, clinical trials, and market expansion. The terms of this engagement, including high fees and expense allowances, are common for smaller companies seeking to raise capital in a competitive market, reflecting the perceived risk and effort involved for the placement agent.

Comparison to Industry Standards

• The 7.0% cash fee and 1.0% management fee for H.C. Wainwright & Co., LLC are at the higher end of typical underwriting/placement agent fees, which generally range from 3% to 7% for smaller offerings in the biotechnology sector. For example, larger, more established biotech companies might secure fees closer to 3-5% for significant public offerings, while smaller, earlier-stage companies often pay 6-7%.
• The expense allowances of up to $90,000 for legal and out-of-pocket costs are also substantial, reflecting the complexity and regulatory burden associated with SEC-registered offerings for development-stage companies.
• The repeated extensions of the engagement term suggest a prolonged capital-raising process, which can be indicative of challenging market conditions or difficulties in attracting investor interest, a common hurdle for emerging growth companies in the biotech space compared to more mature firms like Amgen or Regeneron which have established revenue streams.

Corporate Governance

Legal Proceedings

• A Litigation Funding Agreement dated April 9, 2020, between BSLF, LLC and the Company (Exhibit 10.5) is listed, but no new details or ongoing proceedings are disclosed in this filing.

Stakeholder Impact

• Shareholders: Potential for significant dilution if a capital raise proceeds with the stated fee structure. The delay in the effective date of the S-1 could create uncertainty and impact share price.
• Potential Investors: The terms of the offering, including fees and potential dilution, will be critical for evaluating investment attractiveness. Delays may signal higher risk.
• Employees/Management: Continued engagement with an investment bank suggests efforts to secure funding for ongoing operations, which is positive for job security and strategic initiatives, but delays could create uncertainty.

Next Steps

• File a further amendment to the registration statement to declare its effectiveness.
• Await the SEC's determination for the registration statement to become effective.
• Continue working with H.C. Wainwright & Co., LLC to execute one or more securities offerings.

Key Dates

Recommendation

The company is actively pursuing capital through an exclusive engagement with H.C. Wainwright, which is a necessary step for a development-stage biotechnology firm. However, the repeated extensions of the engagement term and the explicit delay in the S-1's effective date suggest ongoing challenges in securing this financing. While the pursuit of capital is positive, the delays and the potentially high cost of capital (7% cash fee + 1% management fee) introduce uncertainty and potential dilution. Investors should hold and monitor for successful completion of the offering and the terms achieved, as well as progress on clinical programs, before making further investment decisions.

Keywords

BioCardia, S-1/A, SEC filing, capital raise, underwriting agreement, H.C. Wainwright, equity offering, biotechnology, medical devices, financing